Mace Rothenberg

National Academies of Sciences, Engineering, and Medicine. Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop. (The National Academies Press, Washington, DC, 2016). Kemp, R. & Prasad, V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 15, 134 (2017). Wang, Y. et al.

In the modern era of patient-centered drug development, the only way to translate biological and genomic discoveries into clinically meaningful therapies is through partnerships among academia, industry, and government.